Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Evaluate Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us at firstname.lastname@example.org.
Having supplanted Novartis as the biggest pharma company by prescription sales in 2019, Roche managed to hang onto the title in 2020.
There were more than 900 pharmaceutical deals valued at about $800 billion between 2016 and 2020, according to a market-research firm, EvaluatePharma.
Global sales of generics are expected to reach $100 billion by 2024, according to the research firm EvaluatePharma, up from $75 billion in 2018.
The uptick in deals underscores a broader trend in the industry, one in which large, legacy drug makers are buying their pipelines rather than developing new therapies…
The industry prides itself on knowing when to quit, but it’s taking a different approach with cancer treatments.
The $123 billion world-wide cancer-drugs market is expected to almost double by 2024, according to a market-research firm, EvaluatePharma.
Sales of AT132 will reach $38.1 million in 2024, according to EvaluatePharma's sell-side consensus, though this figure will be highly risk adjusted.
EvaluatePharma has projected that the Lynparza will continue to grow to produce annual revenues of $2.2bn by 2024.
Consensus forecasts from EvaluatePharma suggest Zynquista, if it gains approval, could have sales of $1.16 billion by 2022.
EvaluatePharma analysts have previously predicted it could go as high as $6 billion in 2022, staying ahead of its rivals with Novartis and Lilly’s drugs jostling for…
World-wide sales of cholesterol drugs are growing nearly 11% a year and are projected to reach $17.7 billion in 2024, according to EvaluatePharma.
Approved by the FDA in late March for the treatment of relapsing forms of MS, including active secondary progressive MS and relapsing remitting MS, Mayzent’s potential…
Consensus estimates compiled by EvaluatePharma reflect this with forecast sales of Vumerity at a modest $111m in 2024.